Pharming Group (NASDAQ:PHAR) Sees Large Decrease in Short Interest

Pharming Group (NASDAQ:PHAR) was the recipient of a large decline in short interest during the month of December. As of December 15th, there was short interest totalling 10,400 shares, a decline of 48.8% from the November 30th total of 20,300 shares. Based on an average daily trading volume, of 7,400 shares, the short-interest ratio is presently 1.4 days.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the stock. Jefferies Financial Group initiated coverage on shares of Pharming Group in a research note on Monday, December 9th. They set a “buy” rating and a $14.00 price target for the company. Oppenheimer decreased their price objective on Pharming Group from $31.00 to $30.00 and set an “outperform” rating on the stock in a research note on Monday, October 28th. Finally, HC Wainwright restated a “buy” rating and issued a $37.00 target price on shares of Pharming Group in a research note on Tuesday, December 17th.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Pharming Group stock. Silverberg Bernstein Capital Management LLC lifted its holdings in shares of Pharming Group (NASDAQ:PHAR) by 75.4% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 41,110 shares of the company’s stock after buying an additional 17,675 shares during the period. Silverberg Bernstein Capital Management LLC owned approximately 0.06% of Pharming Group worth $339,000 at the end of the most recent reporting period. 0.03% of the stock is owned by hedge funds and other institutional investors.

Pharming Group Trading Down 6.3 %

Shares of Pharming Group stock traded down $0.62 during midday trading on Friday, reaching $9.93. 991 shares of the company’s stock traded hands, compared to its average volume of 5,273. The company has a debt-to-equity ratio of 0.41, a quick ratio of 2.76 and a current ratio of 3.53. Pharming Group has a 12 month low of $6.65 and a 12 month high of $13.20. The company has a market cap of $673.60 million, a PE ratio of -38.19 and a beta of 0.05. The stock has a 50 day moving average of $8.45 and a 200-day moving average of $8.20.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.